You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Top-line results from the first part of the Atalante 1 trial showed the company's investigational product Tedopi produced a 12-month survival rate of 46 percent.
Overexpression of immunoproteasome components PSMB8 and PSMB9 were found to be predictive of improved survival and response to immunotherapy.
